Loading clinical trials...
Loading clinical trials...
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning: a Phase II Randomized Study From the Belgian Hematology Society (BHS)
The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy) to 45% (Pick-a-winner phase 2 randomized study).
This study is a multicenter, randomized, open-label, phase II study pick-a-winner study, comparing 2 conditioning regimens. A total of 114 eligible patients with HLA-matched donors will be randomized 1:1 between the FM-PTCy arm and the FM-ATG arm, with stratification for donor type (related or unrelated). The recruitment period is 3 years with a 5-year follow-up plus a 10-year additional long-term follow-up (for GVHD status, disease status, second malignancy and QOL). The whole study will be completed within 18 years.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
ZNA Stuivenberg
Antwerp, Belgium
AZ Sint Jan Brugge
Bruges, Belgium
IJ Bordet
Brussels, Belgium
UZ Brussel
Brussels, Belgium
UCL St Luc
Brussels, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
CHU de Liège
Liège, Belgium
AZ Delta Roeselare
Roeselare, Belgium
CHU UCL Namur Godinne
Yvoir, Belgium
Start Date
February 4, 2019
Primary Completion Date
November 1, 2033
Completion Date
November 1, 2038
Last Updated
October 12, 2022
114
ESTIMATED participants
Thymoglobulin
DRUG
Melphalan
DRUG
Fludarabine
DRUG
Cyclophosphamid
DRUG
Lead Sponsor
University of Liege
Collaborators
NCT07270978
NCT05292664
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions